chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Bone pain
Clinical narrative: sharp bone pain in R knee, just off the knee cap; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non pregnant female patient received a first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown), via an unspecified route of administration in left arm on Mar2021 as a single dose for COVID-19 immunisation. Medical history included obesity. The patient was allergic to tetracycline-drug allergy and succinyl choline from choline estray deficiency. Concomitant medications included cymbalta (MANUFACTURER UNKNOWN), bupropion (MANUFACTURER UNKNOWN), omeprazole (MANUFACTURER UNKNOWN) and ferrous (MANUFACTURER UNKNOWN) for unknown indications from an unknown duration. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had not tested positive for COVID-19 since having the vaccine. On Mar2021, the patient experienced sharp bone pain in R knee, just off the knee cap developed a day or two after the shot. About a week or so after the shot, the patient thought she had heard a popping noise from her knee and the pain got much worse. The clinical outcome of sharp bone pain was not recovered at the time of report.   Information about lot/batch number cannot be obtained. No further information is expected.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Bone pain, Contraindication to vaccination
Clinical narrative: sharp bone pain in R knee, just off the knee cap; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non pregnant female patient received a first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown), via an unspecified route of administration in left arm on Mar2021 as a single dose for COVID-19 immunisation. Medical history included obesity. The patient was allergic to tetracycline-drug allergy and succinyl choline from choline estray deficiency. Concomitant medications included cymbalta (MANUFACTURER UNKNOWN), bupropion (MANUFACTURER UNKNOWN), omeprazole (MANUFACTURER UNKNOWN) and ferrous (MANUFACTURER UNKNOWN) for unknown indications from an unknown duration. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had not tested positive for COVID-19 since having the vaccine. On Mar2021, the patient experienced sharp bone pain in R knee, just off the knee cap developed a day or two after the shot. About a week or so after the shot, the patient thought she had heard a popping noise from her knee and the pain got much worse. The clinical outcome of sharp bone pain was not recovered at the time of report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Dyspepsia, Fatigue, Headache, Lymphadenopathy
Clinical narrative: fever; Headache; muscle pain; joint pain; injection site pain; swollen lymph nodes in my left arm pit; tiredness; Indigestion; This is a spontaneous report received from a contactable consumer, the patient. A 65-year-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot/batch no: ER2613) via an unspecified route of administration on the left arm on 20Mar2021 at 07:30 AM (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and high cholesterol. The patient was allergic to dye in cat scan. Concomitant medications included metoprolol (MANUFACTURER UNKNOWN) 100 mg, lansoprazole (MANUFACTURER UNKNOWN) 30mg since unknown date and unknown if ongoing. The patient had previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot/batch no: 6198) via an unspecified route of administration on the left arm on 27Feb2021  as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 21Mar2021 at 3:00, the patient experienced fever, headache, muscle pain, joint pain, injection site pain, swollen lymph nodes, indigestion and tiredness. The patient had not received treatment for the reported events. The clinical outcome of fever, headache, muscle pain, joint pain, injection site pain, swollen lymph nodes, indigestion and tiredness were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia, Vaccination site pain
Clinical narrative: fever; Headache; muscle pain; joint pain; injection site pain; swollen lymph nodes in my left arm pit; tiredness; Indigestion; This is a spontaneous report received from a contactable consumer, the patient. A 65-year-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot/batch no: ER2613) via an unspecified route of administration on the left arm on 20Mar2021 at 07:30 AM (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and high cholesterol. The patient was allergic to dye in cat scan. Concomitant medications included metoprolol (MANUFACTURER UNKNOWN) 100 mg, lansoprazole (MANUFACTURER UNKNOWN) 30mg since unknown date and unknown if ongoing. The patient had previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot/batch no: 6198) via an unspecified route of administration on the left arm on 27Feb2021  as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 21Mar2021 at 3:00, the patient experienced fever, headache, muscle pain, joint pain, injection site pain, swollen lymph nodes, indigestion and tiredness. The patient had not received treatment for the reported events. The clinical outcome of fever, headache, muscle pain, joint pain, injection site pain, swollen lymph nodes, indigestion and tiredness were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 90.0
Sex: F
Vaccine: COVID19
Symptoms: Dermatitis allergic
Clinical narrative: allergic reaction rash really bad on her back, arms and neck, legs little bit on her chest; This is a spontaneous report received from a contactable consumer, the patient. A 90-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: 0878346) via an unspecified route of administration in left arm on 06Mar2021 at 12:15 (at the age of 90-year-old), as a single dose, for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disease (COPD), atrial fibrillation and allergy to influenza vaccine. The patient previously received Influenza vaccine on an unknown date. The patient had received unspecified prescribed medications withing two weeks of vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccine 4 weeks prior to COVID vaccine. On 09Mar2021 at 01:00, the patient experienced allergic rash on back, arm, neck and chest, which was really bad. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of allergic rash and included treatment with cream and pills (unspecified) from an unknown date. The clinical outcome of event allergic rash was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Nausea, Pyrexia
Clinical narrative: Joint pain; fatigue; fever; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 72-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205) via unspecified route of administration on 16Mar2021 at 11:45 AM (at the age of 72-year-old) as a single dose for COVID-19 immunisation. The patient medical history included prostate cancer and seasonal allergies. Concomitant medications included gabapentin (MANUFACTURE UNKNOWN), celebrex (MANUFACTURE UNKNOWN), acetaminophen (MANUFACTURE UNKNOWN), allegra (MANUFACTURE UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. It was reported that the patient did not received any other vaccines within 4 weeks prior to the COVID vaccine. On 19Mar2021, the patient experienced joint pain, fatigue, fever and nausea. The clinical outcome of the events joint pain, fatigue, fever and nausea were not recovered at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Somnolence
Clinical narrative: Mild headaches/Stronger headache; Sleepiness; This is a spontaneous report received from a contactable consumer, the patient. A 64-year-old non- pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 15Mar2021at 11:00 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. The patient's medical history included cancer in 2015 and 2016 which was fully recovered. The patient did not have any allergies to medications, food, or other products. Concomitant medications included DEXILANT, LINZESS and PRISTIQ; all for unknown indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 22Feb2021 at 11:00 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not been diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 15Mar2021, the patient experienced mild headaches and sleepiness first four days post vaccination. On the eight-day, the patient still had achiness and stronger headache. The patient did not receive any treatment for the events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headaches and sleepiness were not recovered at the time of reporting.  Information about lot/batch number cannot be obtained. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Fatigue, Pain, Pyrexia
Clinical narrative: pain severe back; Fatigue; fever extreme; so much pain; This is a spontaneous report received from a contactable consumer, the patient. A 63-year-old non pregnant female patient received unspecified dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot/batch no: UNKNOWN) via an unspecified route of administration (at the age of 63-year-old) as a single dose on 20Mar2021 at 11:00hours for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient was not allergic to medications, food, or other products. The patient experienced pain severe back pain much like you would get when you have flu felling flush and fever extreme fatigue, so much pain that she had to leave work on 21Mar2021 at 07:00. No therapeutic measures were taken for the resulted adverse events. The clinical outcome of the event back pain, fever and fatigue and so much pain was not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch no cannot be obtained.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Anxiety, Chills, Dizziness, Hyperhidrosis
Clinical narrative: Diaphoresis; Dizzy/lightheaded; Increased anxiety; Chills; This is spontaneous report from non-contactable other healthcare professional. A 46-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205), via an unspecified route of administration, on 18Mar2021, (at the age of 46-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. On 18Mar2021, during 15-minute waiting period after the vaccination, the patient experienced diaphoresis, dizzy/lightheaded and increased anxiety. The patient also complained of chills and dizziness. The patient denied rash, hives, difficulty breathing, difficulty swallowing, wheezing, throat tightness, hoarseness, stridor, itching, light headedness, dizziness, facial swelling, lip swelling and tongue swelling. The patient received treatment as a result of adverse events experienced which included water, snacks and laying down. The patient had excellent response to treatment. The patient was stable to go home and was asked to follow up with primary care physician (PCP). The clinical outcome of diaphoresis, dizzy/lightheaded, increased anxiety and chills were recovered on 18Mar2021.   No follow-up attempts are possible. No further information is expected.
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Hiccups
Clinical narrative: Uncontrolled hiccups; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the right arm on 11Mar2021 at 10:00 (at the age of 36-year-old), as a single dose for COVID-19 immunisation. The medical history included suspected COVID-19 in Jan2021 but rapid tested negative and became asymptomatic in Mar2020, asthmatic and Type 2 Diabetes mellitus (T2D). Concomitant medication included montpellier metformina clorhidrato (MANUFACTURER UNKNOWN) 500 mg per day for unknown indication. The patient was allergic to seasonal and pets. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination patient was not diagnosed with COVID-19. The patient had not tested positive for COVID-19 since vaccination. On 18Mar2021 at 06:00, the patient experienced uncontrolled hiccups after food ingest that stopped only under the following circumstances such as symptoms arose on 3/17 and had not ceased since high intensity while exercises and sleep. The patient did not receive treatment for the reported events. Event resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event uncontrolled hiccups was not resolved at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: injection site still swollen, red and itching frequently; injection site still swollen, red and itching frequently; injection site still swollen, red and itching frequently; This is a spontaneous report from a contactable consumer, the patient. A 40-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6207) via an unspecified route of administration in the left arm on 14Mar2021 at 09:45 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The patients medical history included systemic lupus erythematosus (lupus SLE as reported). The patient had no known allergies to medications, food, or other products. The patient did not receive any other medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 14Mar2021, the patient experienced injection site swelling, red and itching. The patient reported that 1 week later, injection site was still swollen, red and itching frequently. Therapeutic measures were taken as a result of events and included treatment with ice packs and ibuprofen. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of vaccination site swelling, vaccination site erythema and injection site itching were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain, Skin warm
Clinical narrative: Achy; warm; tired; This is a spontaneous report from a contactable consumer, the patient. A 61-years-old non-pregnant female patient received first single dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP7534), via an unspecified route of administration on left arm on 16March2021 at 16:30 for COVID-19 vaccination. Medical history included familial medullary thyroid carcinoma for past 30 years. It is unknown whether the patient was having any known allergies. The concomitant medications included SYNTHROID 200mg, DIEHTYLPROPIONER 75 mg. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested positive for COVID-19. The patient not had any symptoms associated with COVID-19. The patient did not receive any other vaccine within four weeks prior to vaccine. On 18Mar2021 at 12:00 (started two days after the first dose), the patient feels achy, warm and tired starting around noon each day. The patient had not running a temperature. It was reported that, the patient working from home, so had not been anywhere when it started, other than getting the Patients first vaccination. It's a daily recurrence. The patient did not receive any other treatment for the adverse event. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events ache, warm and tired was not resolved at the time of this report.   No follow up attempts are needed. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: swollen lymph nodes on left side of neck; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: en6208) via an unspecified route of administration in the left arm on 17Mar2021 at 12:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. The patients medical history was not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. Since the vaccination, the patient has not tested for COVID-19. On 21Mar2021 at 00:00, the patient experienced swollen lymph node on left side of neck. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken for the event swollen lymph nodes. The clinical outcome of the event swollen lymph node was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Limb injury, Pruritus
Clinical narrative: Arm itched 9 days after for about 12 hours; Arm hurt for 48 hours; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EP7534) via an unspecified route of administration in right arm on 13Mar2021 at 09:45 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. The medical history included eczema. The patient had allergies to penicillin. Concomitant medications included topical steroids, estrogen (MANUFACTURER UNKNOWN) and progesterone (MANUFACTURER UNKNOWN), all from unknown dates and for unknown indications. The patient did not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient was not diagnosed with COVID-19 prior to the vaccination. Since the vaccination, the patient had not been tested positive for COVID-19. On 14Mar2021 at 21:00, the patient experienced arm hurt (arm injury) for 48 hours and 9 days after on 22Mar2021, the patient arm was itched (itchy) for about 12 hours. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events arm injury was resolved on 16Mar2021 and itchy was resolved on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Dyskinesia
Clinical narrative: Uncontrolled muscle movements primarily in left arm/hand.; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the right arm on 21Mar2021 at 09:45 (at the age of 31-years-old), as a single dose for COVID-19 immunisation. Medical history included latex allergy. Concomitant medication was not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. On 21Mar2021, the patient experienced uncontrolled muscle movements, primarily in the left arm. The muscle movements occurred approximately every 2 hours and lasted for 30-60 seconds. The patient did not receive any treatment for the event. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of uncontrolled muscle movements was not recovered at the time of this report.  Information about lot/batch number cannot be obtained. No further information is expected.
Age: 25.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Vaccination site pain
Clinical narrative: sore arm at site of injection; brief headache; This is a spontaneous report from a contactable pharmacist. A 25-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown), via intramuscular route of administration in the right arm on 20Mar2021 at 10:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have any known allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had not been tested for COVID-19 since having the vaccine. On 20Mar2021, the patient experienced sore arm at site of injection and brief headache. The date of awareness of this event was reported as 21Mar2021. The patient did not receive any treatment for events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of sore arm at site of injection and brief headache was unknown.   Information about lot number cannot be obtained. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Vaccination site bruising
Clinical narrative: Injection site bruise; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207), via an unspecified route of administration in the left arm on 19Mar2021 at 09:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and dysthymia. Concomitant medications included PROZAC, levothyroxine (MANUFACTURER UNKNOWN); both for unspecified indication from unknown dates. The patient did not have any allergies to food, medications, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient had not been diagnosed with COVID-19. Since the vaccination, the patient did not test for COVID-19. On 19Mar2021 at 17:00, the patient experienced injection site bruise and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the event vaccination site bruising and fatigue was resolved on unknown date of Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Lymphadenopathy
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 52-year-old adult non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER8727) via an unspecified route of administration on left arm on 18Mar2021 at 07:00 as a single dose (at the age of 53-year-old) for COVID-19 immunisation. The patient medical history and concomitant medication was not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6205) via an unspecified route of administration on left arm on 28Feb2021 at 15:30 as a single dose for COVID-19 immunisation. The patient reported no allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient did not receive any medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested positive for COVID-19. On 20Mar2021 at 12:00, the patient experienced swollen lymph nodes on injection arm and on 21Mar2021, the patient experienced lower back pain. No treatment was received for these events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of swollen lymph node and lower back pain was recovered.   No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity, Viral test
Clinical narrative: Sore and tight in left arm; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old adult male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA vaccine; Lot number: UNKNLOWN), via an unspecified route of administration in the left arm on 07Mar2021 at 14:45 (at the age of 31 years old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included fluticasone(ARNUITY ELLIPTA) for unknown indication from unknown date. The patient did not have known allergies to medications, food, or other products. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. On 09Mar2021, the patient experienced sore and tight in left arm (where injection was received) on the underneath side of the arm, spanning from bottom of armpit to elbow. No heat or swelling, just a dull and uncomfortable sensation. The patient underwent lab tests and procedures, which included COVID-19 Virus test on unknown date and resulted negative. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported event. The clinical outcome of pain in arm was recovering.   Information about lot number cannot be obtained. No further information is expected.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Eye swelling, Muscle tightness, Periorbital swelling
Clinical narrative: Left side of neck felt getting tight, likea constricted muscle; Eyes also became swollen with puffy eyelids; Eyes also became swollen with puffy eyelids.; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP7534) via an unspecified route of administration in the left arm on 18Mar2021 at 13:30 (at the age of 39-years-old), as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis. The patient did not receive any other vaccines within four weeks prior to the vaccination. Patient received other medication within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 18Mar2021 at 15:00, the patient felt the left side of his neck getting tight, like a constricted muscle and eyes also became swollen with puffy eyelids. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown if the patient received any treatment for the events neck tightness, swollen eyelids and puffy eyes. The clinical outcome of the events neck tightness, swollen eyelids and puffy eyes was not recovered at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Dizziness, Fatigue, Nausea
Clinical narrative: Chills; Shaking; Body joint ache; Sore arm; Slight dizziness; Fatigue; Nausea; This is a spontaneous report from a contactable other healthcare professional, the patient. A 22-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an unspecified route of administration in the left arm on 20Mar2021 at 11:30 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient did not receive any concomitant medication in two weeks prior to the COVID-19 vaccine. The patient was not allergic medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 19:30, the patient experienced chills, shaking, body joint ache, sore arm, slight dizziness, fatigue, and nausea. The treatment received for the adverse events included ibuprofen. The clinical outcome of chills, shaking, body joint ache, sore arm, slight dizziness, fatigue, and nausea was recovered on an unspecified date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, SARS-CoV-2 test, Tremor
Clinical narrative: Chills; Shaking; Body joint ache; Sore arm; Slight dizziness; Fatigue; Nausea; This is a spontaneous report from a contactable other healthcare professional, the patient. A 22-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an unspecified route of administration in the left arm on 20Mar2021 at 11:30 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient did not receive any concomitant medication in two weeks prior to the COVID-19 vaccine. The patient was not allergic medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 19:30, the patient experienced chills, shaking, body joint ache, sore arm, slight dizziness, fatigue, and nausea. The treatment received for the adverse events included ibuprofen. The clinical outcome of chills, shaking, body joint ache, sore arm, slight dizziness, fatigue, and nausea was recovered on an unspecified date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Lymph node pain, Pruritus, Vaccination site erythema, Vaccination site mass
Clinical narrative: Itchiness; redness on arm below injection point; tenderness and around lymph node under arm.; pain under arm; Hard knot at injection site; Hard knot and tenderness at injectionpoint; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in right arm on 18Mar2021 at 12:00 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and high cholesterol. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and rosuvastatin (MANUFACTURER UNKNOWN) taken from unknown dates for unknown indications. Prior to vaccination, on an unknown date, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Since the vaccination, the patient was not diagnosed with COVID-19. On 18March2021, the patient experienced a hard knot and tenderness at injection site; on 19Mar2021, experienced pain under arm; on 20Mar2021, redness below injection point and tenderness around lymph node underarm and 3-4 days later to vaccination, experienced expanded redness on arm below injection point with pain and itchiness. Therapeutic measures were not taken as a result of the events. The clinical outcome for events vaccination site lump, vaccination site tenderness, armpit pain, itchiness, redness and lymph node tender were recovering.  No follow-up attempts are possible. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Itchiness; redness on arm below injection point; tenderness and around lymph node under arm.; pain under arm; Hard knot at injection site; Hard knot and tenderness at injectionpoint; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in right arm on 18Mar2021 at 12:00 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and high cholesterol. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and rosuvastatin (MANUFACTURER UNKNOWN) taken from unknown dates for unknown indications. Prior to vaccination, on an unknown date, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Since the vaccination, the patient was not diagnosed with COVID-19. On 18March2021, the patient experienced a hard knot and tenderness at injection site; on 19Mar2021, experienced pain under arm; on 20Mar2021, redness below injection point and tenderness around lymph node underarm and 3-4 days later to vaccination, experienced expanded redness on arm below injection point with pain and itchiness. Therapeutic measures were not taken as a result of the events. The clinical outcome for events vaccination site lump, vaccination site tenderness, armpit pain, itchiness, redness and lymph node tender were recovering.  No follow-up attempts are possible. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swollen Lymph Nodes under left armpit; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot number: EN6206), via an unspecified route of administration in the left arm on 06Mar2021 at 15:15 (at the age of 47-years-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient was allergic to codeine (MANUFACTURER UNKNOWN). The concomitant medications included hydrochlorothiazide tabs 25mg (MANUFACTURER UNKNOWN), ascorbic acid (VITAMIN C) and cholecalciferol (VITAMIN D3) for unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA vaccine; Lot number: EL9266), via an unspecified route of administration in the left arm on 13Feb2021 at 15:15, as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the vaccine. Prior to vaccination, the patient had no symptoms associated for COVID-19. Since the vaccination, the patient was not tested positive for COVID-19. On 07Mar2021, the patient had swollen lymph nodes under left armpit. The patient did not receive any treatment for reported events. The clinical outcome of swollen lymph nodes under left armpit was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Headache, Lethargy, Pain, Restlessness
Clinical narrative: Lethargy; Mild headache; chills; Mild soreness; Restlessness followed; This is a spontaneous report from a contactable consumer, the patient. A 53-years-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via unspecified route of administration in the right arm on 16Mar2021 at 09:45 (at the age of 53-year-old), as a single dose for COVID-19 immunisation. The patient had no medical and known allergic history. Concomitant medication included glucosamine (MANUFACTURER UNKNOWN), one a day for men at the age of 50 plus. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine and was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 16Mar2021, the patient had experienced mild soreness, 11 hours later at 22:00 severe chills which were strong enough that the patient could not carry a glass of water without spilling it and restlessness followed. On 17Mar2021, next day the patient experienced lethargy and mild headache which continued in the evenings for 2 days. The Patient did not receive any treatment for the events. Event had not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcomes for the events chills, was recovered on 17Mar2021 at 02:00, lethargy and mild headache were recovered on 19Mar2021, restlessness and soreness were recovered on an unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Illness, Nausea, Pyrexia
Clinical narrative: very ill; Fever; no energy; nauseous; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route administration in the right arm on 16Mar2021 at 00:00, (at the age of 53-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not have allergies to medications, food, or other products. On 16Mar2021 at 20:00, the patient experienced fever, no energy, nauseous and very ill. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events illness, fever, loss of energy and nauseous was not recovered at the time of this report.   Information about lot number cannot be obtained. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pain in extremity, Pyrexia, Somnolence
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 55-years-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route in left arm on Mar2021 at 09:45 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient was not tested for COVID-19. Concomitant medication included levothyroxine sodium (MANUFACTURER UNKNOWN) 137 mg for unknown indication. On 18Mar2021 at 10:00, the patient experienced arm soar, headache, slight fever, tired and sleepy. Therapeutic measures taken for these events included treatment with Tylenol and sleep. The clinical outcome of the events arm soar, headache, slight fever, tired and sleepy were resolved on unspecified date in Mar2021.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Fatigue, Headache, Myalgia
Clinical narrative: Fever; Fatigue; Headache; Muscle pain; Joint pain; Chills; Nausea; This is a spontaneous report received from a contactable other health professional, the patient. A 53-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via unspecified route of administration in the left arm on 20Mar2021 at 11:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patients medical history and concomitant medications were not provided. The patient previously took omeprazole (MANUFACTURER UNKNOWN) for unknown indication and experienced drug allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had not been tested for COVID-19, since the vaccination. On 21Mar2021 at 14:00, the patient experienced fever, fatigue, headache, muscle pain, joint pain, chills and nausea. The patient underwent lab tests and procedures, which included PCR (nasal swab/Flu/COVID-19) on an unknown date and resulted negative. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care visit. The patient did not receive treatment for the reported event. The clinical outcome of the fever, fatigue, headache, muscle pain, joint pain, chills and nausea was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pyrexia, SARS-CoV-2 test
Clinical narrative: Fever; Fatigue; Headache; Muscle pain; Joint pain; Chills; Nausea; This is a spontaneous report received from a contactable other health professional, the patient. A 53-year-old non pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via unspecified route of administration in the left arm on 20Mar2021 at 11:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patients medical history and concomitant medications were not provided. The patient previously took omeprazole (MANUFACTURER UNKNOWN) for unknown indication and experienced drug allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had not been tested for COVID-19, since the vaccination. On 21Mar2021 at 14:00, the patient experienced fever, fatigue, headache, muscle pain, joint pain, chills and nausea. The patient underwent lab tests and procedures, which included PCR (nasal swab/Flu/COVID-19) on an unknown date and resulted negative. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care visit. The patient did not receive treatment for the reported event. The clinical outcome of the fever, fatigue, headache, muscle pain, joint pain, chills and nausea was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Headache, Malaise
Clinical narrative: Nausea; Headache; Chills; Dizziness; Feeling unwell; Tiredness; Pain at injection site; Could not sleep the night of thesecond vaccine.; This is a spontaneous report from a contactable consumer, the patient. A 75-year-old-female non-pregnant patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205), via an unspecified route of administration in the left arm on 06Mar2021 at 01:45 for COVID-19 immunisation. Medical history included penicillin allergy. Concomitant medications included DYAZIDE, vitamin C (MANUFACTURER UNKNOWN), vitamin D (MANUFACTURER UNKNOWN), fish Oil (MANUFACTURER UNKNOWN), biotin (MANUFACTURER UNKNOWN) and flavonoid (MANUFACTURER UNKNOWN); all were taken for unknown indication from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9266), via an unspecified route of administration in the left arm on 13Feb2021 at 01:45 for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient was tested for COVID-19. The patient has not received any other vaccines within 4 weeks prior to the COVID vaccine. On 06Mar2021, the patient could not sleep the night of the second vaccine and experienced nausea, headache, chills, dizziness, feeling unwell, tiredness and pain at injection site at night. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No treatment was received for the adverse events. The clinical outcome of the events could not sleep the night of the second vaccine, nausea, headache, chills, dizziness, feeling unwell, tiredness and pain at injection site was recovered (all for a couple of days) at the time of reporting.   No follow-up attempts are needed. No further information is expected.